Hemogenyx shares jump 13% as first-in-human trial of CAR-T therapy begins
Portfolio Pulse from
Hemogenyx Pharmaceuticals' shares rose by 13% after the company announced the first human dose of its CAR-T cell therapy, HG-CT-1, targeting acute myeloid leukemia.
February 24, 2025 | 9:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hemogenyx Pharmaceuticals' shares increased by 13% following the initiation of human trials for their CAR-T therapy, HG-CT-1, aimed at treating acute myeloid leukemia.
The initiation of human trials for a new CAR-T therapy is a significant milestone for Hemogenyx, indicating progress in their product development. This news has positively impacted their stock price, reflecting investor optimism about the potential success of the therapy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100